Når BYETTA tilføjes eksisterende metformin- behandling, kan den aktuelle dosering af metformin fortsættes, da der ikke forventes øget risiko for hypoglykæmi sammenlignet med metformin alene.
When BYETTA is added to existing metformin therapy, the current dose of metformin can be continued as no increased risk of hypoglycaemia is anticipated, compared to metformin alone.